Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. This is a 91.03 percent increase over losses of $(3.12) per share from the same period last year.